Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f9ba6891833253cb01df130b76127e4b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed5f0aa1fc6a288a1389a6a0c24c9f97 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_55e762b26fbbe1a271b86d4ae8dced7b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8c1988a6e8b7bbebcd15c831d72ade67 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae0412e72f24b7aea064b1505c6cc11c |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96455 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N21-64 |
filingDate |
2012-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2c1e33d931a63cbc125495026612604 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4358339c6df644dc89e4f2ce6f318f22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c801761961bcb511d25819cda25e6d2c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30b38d9c7442b40da1a55f2e57600277 |
publicationDate |
2012-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2012309007-A1 |
titleOfInvention |
Prostate cancer prognostic compositions and kits |
abstract |
Described herein are method, compositions and kits for prognosis of prostate cancer. The methods comprise: determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The present invention features a method for prognosing prostate cancer in a sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11105808-B2 |
priorityDate |
2004-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |